Psoriasis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining the LITE study in plaque-type psoriasis.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the SPROUT study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the BE BRIGHT study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the FRONTIER-2 study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 STRIDE study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 KNOCKOUT study.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.

Tildrakizumab was efficacious in the treatment of patients with moderate to severe plaque psoriasis affecting the scalp and presented no new safety signals, according to a study.

Once-daily roflumilast cream 0.3% was well tolerated and efficacious in the long-term treatment of patients with plaque psoriasis, suggesting it is suitable for chronic treatment, according to a study.

The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study.